Ocular Therapeutix Inc (OCUL) is Trading Lower on Unusual Volume for February 18

Equities Staff |

Ocular Therapeutix Inc (OCUL) experienced unusually high volume on Feb. 18, as the stock lost 5.25% to a closing price of $8.22. The stock saw 650,856 shares trade hands over the course of the day on 3,610 trades. Given that the stock’s average daily volume over the last month has been 423,085 shares a day, this represents a pretty substantial spike over the norm.

Ocular Therapeutix Inc has a P/B ratio of 2.06. The stock has traded between $44.19 and $5.07 over the last 52-weeks, its 50-day SMA is now $7.64, and its 200-day SMA $15.59.

Ocular Therapeutix Inc is a biopharmaceutical company focused on the development and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology.

Headquartered in Bedford, MA, Ocular Therapeutix Inc has 74 employees and is currently under the leadership of CEO Amarpreet Sawhney.

For a complete fundamental analysis analysis of Ocular Therapeutix Inc, check out Equities.com’s Stock Valuation Analysis report for OCUL. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.


The Russell 3000 is not well known outside the world of finance, but it’s one of the strongest indices out there for getting a broad sense of the stock market. Unlike the better-known Dow Jones Industrial Average or S&P 500, membership on the Russell 3000 isn’t selected by committee. It’s simply the 3,000 most valuable companies in the country.

With 3,000 stocks making up the index, it gives a broad look at the markets, including the small-and mid-cap companies that aren’t on the Dow or the S&P 500. And with a rules-based system for determining membership, there’s no bias that could potentially limit membership. That’s why many financial professionals will turn to the Russell 3000 long before the better-known indices when trying to take the temperature of the market.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets

BioSculpture Technology, Inc.

BioSculpture Technology, Inc. (“BST”) is a commercial-stage medical device manufacturer of liposuction surgical instruments for surgeons. It offers the FDA-cleared Twin Cannula Assisted Liposuction ("TCAL") Airbrush Liposculptor II® controllers, Airbrush®…

Quants Inc

Quants, Inc, a California Corporation, develops, markets and operates financial technology platforms and alternative investment products offering sophisticated risk management since 2010. The Company has primarily sharpened its focus with…